Business Description
Kiniksa Pharmaceuticals International PLC
NAICS : 325412
SIC : 2833
ISIN : GB00BRXB0C07
Share Class Description:
KNSA: Class ATotal Employee Number:
366Compare
Compare
Traded in other countries / regions
KNSA.USAKNSAN.Mexico Index Membership
Russell 3000Russell 2000 IPO Date
2018-05-24Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 59.11 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.09 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 16.18 | |||||
Beneish M-Score | -3.2 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 40 | |||||
3-Year EBITDA Growth Rate | 79.3 | |||||
3-Year EPS without NRI Growth Rate | -33.9 | |||||
3-Year FCF Growth Rate | 177.3 | |||||
3-Year Book Growth Rate | 9.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 57.04 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 26.71 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34 | |||||
9-Day RSI | 42.38 | |||||
14-Day RSI | 49.1 | |||||
3-1 Month Momentum % | 50.83 | |||||
6-1 Month Momentum % | 68 | |||||
12-1 Month Momentum % | 110.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.9 | |||||
Quick Ratio | 3.49 | |||||
Cash Ratio | 3.07 | |||||
Days Inventory | 55.06 | |||||
Days Sales Outstanding | 12.67 | |||||
Days Payable | 10.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.1 | |||||
Shareholder Yield % | 0.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.5 | |||||
Operating Margin % | 11.92 | |||||
Net Margin % | 9.59 | |||||
EBITDA Margin % | 12.14 | |||||
FCF Margin % | 21.74 | |||||
OCF Margin % | 22 | |||||
ROE % | 14.11 | |||||
ROA % | 10.45 | |||||
ROIC % | 25.72 | |||||
3-Year ROIIC % | 101.85 | |||||
ROC (Joel Greenblatt) % | 840.49 | |||||
ROCE % | 15.91 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 78.63 | |||||
Forward PE Ratio | 41.84 | |||||
PE Ratio without NRI | 78.63 | |||||
Price-to-Owner-Earnings | 46.25 | |||||
PS Ratio | 7.44 | |||||
PB Ratio | 9.09 | |||||
Price-to-Tangible-Book | 9.3 | |||||
Price-to-Free-Cash-Flow | 34.29 | |||||
Price-to-Operating-Cash-Flow | 33.88 | |||||
EV-to-EBIT | 54.2 | |||||
EV-to-EBITDA | 53.25 | |||||
EV-to-Revenue | 6.46 | |||||
EV-to-Forward-Revenue | 4.66 | |||||
EV-to-FCF | 29.72 | |||||
Price-to-GF-Value | 1.37 | |||||
Price-to-Projected-FCF | 11.3 | |||||
Price-to-Graham-Number | 5.7 | |||||
| Price-to-Net-Current-Asset-Value | 13.94 | |||||
| Price-to-Net-Cash | 20.95 | |||||
Earnings Yield (Greenblatt) % | 1.85 | |||||
FCF Yield % | 3.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KNSA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kiniksa Pharmaceuticals International PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 840.848 | ||
| EPS (TTM) ($) | 0.97 | ||
| Beta | 0.1 | ||
| 3-Year Sharpe Ratio | 1.34 | ||
| 3-Year Sortino Ratio | 3.69 | ||
| Volatility % | 39.49 | ||
| 14-Day RSI | 49.1 | ||
| 14-Day ATR ($) | 2.666112 | ||
| 20-Day SMA ($) | 78.798 | ||
| 12-1 Month Momentum % | 110.21 | ||
| 52-Week Range ($) | 35.2 - 82.94 | ||
| Shares Outstanding (Mil) | 78.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kiniksa Pharmaceuticals International PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kiniksa Pharmaceuticals International PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 08:30 | In 166 days | ||
| Annual report for 2026 | 2027-02-24 | In 165 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 165 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-28 08:30 | In 47 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 46 days | ||
| Wells Fargo 21st Annual Healthcare Conference | 2026-09-09 08:45 | 77.09 (+1.10%) | ||
| Canaccord Genuity 46(th) Annual Growth Conference | 2026-08-12 09:00 | 77.80 (+1.47%) | ||
| Second quarter earnings conference call for 2026 | 2026-07-28 08:30 | 63.54 (+0.91%) | ||
| Second quarter earnings results for 2026 | 2026-07-28 | 63.54 (+0.91%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 11:20 | 49.04 (+0.49%) |
Show
Entries
Kiniksa Pharmaceuticals International PLC Frequently Asked Questions
What is Kiniksa Pharmaceuticals International PLC(KNSA)'s stock price today?
The current price of KNSA is $76.18. The 52 week high of KNSA is $82.94 and 52 week low is $35.20.
When is next earnings date of Kiniksa Pharmaceuticals International PLC(KNSA)?
The next earnings date of Kiniksa Pharmaceuticals International PLC(KNSA) is 2026-10-28 Est..
Does Kiniksa Pharmaceuticals International PLC(KNSA) pay dividends? If so, how much?
Kiniksa Pharmaceuticals International PLC(KNSA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers